연구논문

세부과제번호 2014M3A9D5A01075128 단계 2단계 1차년도
세부과제명 유전자변형마우스 제작 및 개발 공동 유/무 N
SCI여부 Y 게재년월 2016-12
논문제목 The Hippo signaling pathway provides novel anti-cancer drug targets.
총저자명 June Sung Bae, Sun Mi Kim, Ho Lee
학술지명 Oncotarget 게재권(호) 8(9)
저널구분 - 페이지수 16084-16098
참여연구원 - 연구책임자 이호
과제기여도 30 PMID 28035075
사사기관수 - IF (년도) 5.168
제1저자 June Sung Bae 교신저자 Ho Lee
공동저자 Sun Mi Kim
초록
The Hippo signaling pathway plays a crucial role in cell proliferation, apoptosis, differentiation, and development. Major effectors of the Hippo signaling pathway include the transcriptional co-activators Yes-associated protein 1 (YAP) and WW domain-containing transcription regulator protein 1 (TAZ). The transcriptional activities of YAP and TAZ are affected by interactions with proteins from many diverse signaling pathways as well as responses to the external environment. High YAP and TAZ activity has been observed in many cancer types, and functional dysregulation of Hippo signaling enhances the oncogenic properties of YAP and TAZ and promotes cancer development. Many biological elements, including mechanical strain on the cell, cell polarity/adhesion molecules, other signaling pathways (e.g., G-protein-coupled receptor, epidermal growth factor receptor, Wnt, Notch, and transforming growth factor β/bone morphogenic protein), and cellular metabolic status, can promote oncogenesis through synergistic association with components of the Hippo signaling pathway. Here, we review the signaling networks that interact with the Hippo signaling pathway and discuss the potential of using drugs that inhibit YAP and TAZ activity for cancer therapy.
다음글
이전글